D
Arcadia Biosciences, Inc.
RKDA
$3.40
-$0.0813-2.34%
D
Sell
12/13/2024Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 12/13/2024 due to a noticeable increase in the total return index and volatility index.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 12/13/2024 due to a noticeable increase in the total return index and volatility index.
E
Sell
4/5/2023Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 4/5/2023 due to a decline in the efficiency index and total return index. Net income declined 48.03% from -$2.87M to -$4.24M, and total capital declined 15.97% from $27.27M to $22.92M.
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 4/5/2023 due to a decline in the efficiency index and total return index. Net income declined 48.03% from -$2.87M to -$4.24M, and total capital declined 15.97% from $27.27M to $22.92M.
D
Sell
3/16/2023Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 3/16/2023 due to an increase in the valuation index.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 3/16/2023 due to an increase in the valuation index.
E
Sell
3/1/2023Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 3/1/2023 due to a decline in the valuation index, volatility index and total return index.
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 3/1/2023 due to a decline in the valuation index, volatility index and total return index.
D
Sell
8/15/2022Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to D- from D on 8/15/2022 due to a large decline in the growth index and solvency index. Debt to equity increased from 0.03 to 0.04, and the quick ratio declined from 5.68 to 5.29.
Arcadia Biosciences, Inc. (RKDA) was downgraded to D- from D on 8/15/2022 due to a large decline in the growth index and solvency index. Debt to equity increased from 0.03 to 0.04, and the quick ratio declined from 5.68 to 5.29.
D
Sell
5/16/2022Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D from D- on 5/16/2022 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.4182 to -$0.2023, total revenue increased 48.32% from $2.17M to $3.22M, and operating cash flow increased 26.65% from -$6.66M to -$4.89M.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D from D- on 5/16/2022 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.4182 to -$0.2023, total revenue increased 48.32% from $2.17M to $3.22M, and operating cash flow increased 26.65% from -$6.66M to -$4.89M.
D
Sell
4/18/2022Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to D- from D on 4/18/2022 due to a significant decline in the valuation index, efficiency index and growth index. Net income declined 326.76% from -$2.18M to -$9.28M, earnings per share declined from -$0.0981 to -$0.4182, and total capital declined 21.67% from $44.03M to $34.49M.
Arcadia Biosciences, Inc. (RKDA) was downgraded to D- from D on 4/18/2022 due to a significant decline in the valuation index, efficiency index and growth index. Net income declined 326.76% from -$2.18M to -$9.28M, earnings per share declined from -$0.0981 to -$0.4182, and total capital declined 21.67% from $44.03M to $34.49M.
D
Sell
11/17/2021Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D from D- on 11/17/2021 due to a significant increase in the valuation index, efficiency index and growth index. Total revenue increased 69.11% from $1.41M to $2.38M, net income increased 58.66% from -$5.26M to -$2.18M, and earnings per share increased from -$0.2419 to -$0.1.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D from D- on 11/17/2021 due to a significant increase in the valuation index, efficiency index and growth index. Total revenue increased 69.11% from $1.41M to $2.38M, net income increased 58.66% from -$5.26M to -$2.18M, and earnings per share increased from -$0.2419 to -$0.1.
D
Sell
11/8/2021Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index and total return index. Earnings per share declined from $0.1085 to -$0.2419, operating cash flow declined 32.42% from -$4.71M to -$6.23M, and EBIT declined 30% from -$5.26M to -$6.83M.
Arcadia Biosciences, Inc. (RKDA) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index and total return index. Earnings per share declined from $0.1085 to -$0.2419, operating cash flow declined 32.42% from -$4.71M to -$6.23M, and EBIT declined 30% from -$5.26M to -$6.83M.
D
Sell
11/19/2020Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D from D- on 11/19/2020 due to a major increase in the growth index. Earnings per share increased from -$1.04 to -$0.6, EBIT increased 12.19% from -$6.88M to -$6.04M, and total revenue increased 11.74% from $281 to $314.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D from D- on 11/19/2020 due to a major increase in the growth index. Earnings per share increased from -$1.04 to -$0.6, EBIT increased 12.19% from -$6.88M to -$6.04M, and total revenue increased 11.74% from $281 to $314.
D
Sell
8/14/2020Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to D- from D on 8/14/2020 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $0.29 to -$1.0388, EBIT declined 18.76% from -$5.79M to -$6.88M, and total revenue declined 9.06% from $309 to $281.
Arcadia Biosciences, Inc. (RKDA) was downgraded to D- from D on 8/14/2020 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $0.29 to -$1.0388, EBIT declined 18.76% from -$5.79M to -$6.88M, and total revenue declined 9.06% from $309 to $281.
D
Sell
5/1/2020Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, volatility index and growth index. Earnings per share increased from -$2.0435 to -$0.7207, EBIT increased 19.44% from -$6.19M to -$4.99M, and total revenue increased 6.12% from $392 to $416.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, volatility index and growth index. Earnings per share increased from -$2.0435 to -$0.7207, EBIT increased 19.44% from -$6.19M to -$4.99M, and total revenue increased 6.12% from $392 to $416.
D
Sell
9/18/2019Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 9/18/2019 due to an increase in the valuation index and total return index.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 9/18/2019 due to an increase in the valuation index and total return index.
E
Sell
8/23/2019Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 8/23/2019 due to a decline in the total return index and volatility index.
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 8/23/2019 due to a decline in the total return index and volatility index.
D
Sell
7/9/2018Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to D- from D on 7/9/2018 due to a decline in the volatility index and total return index.
Arcadia Biosciences, Inc. (RKDA) was downgraded to D- from D on 7/9/2018 due to a decline in the volatility index and total return index.
D
Sell
5/11/2018Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D from D- on 5/11/2018 due to a noticeable increase in the total return index and volatility index.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D from D- on 5/11/2018 due to a noticeable increase in the total return index and volatility index.
D
Sell
3/12/2018Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 3/12/2018 due to an increase in the volatility index, growth index and total return index.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 3/12/2018 due to an increase in the volatility index, growth index and total return index.
E
Sell
11/13/2017Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 11/13/2017 due to a decline in the efficiency index, growth index and volatility index. Total capital declined 73.32% from $39.99M to $10.67M, total revenue declined 40.57% from $991 to $589, and earnings per share declined from -$0.0939 to -$0.11.
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 11/13/2017 due to a decline in the efficiency index, growth index and volatility index. Total capital declined 73.32% from $39.99M to $10.67M, total revenue declined 40.57% from $991 to $589, and earnings per share declined from -$0.0939 to -$0.11.
D
Sell
8/11/2017Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 8/11/2017 due to an increase in the efficiency index, growth index and volatility index. EBIT increased 5.7% from -$3.96M to -$3.74M, net income increased 4.98% from -$4.22M to -$4.01M, and operating cash flow increased 3.16% from -$4.53M to -$4.39M.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 8/11/2017 due to an increase in the efficiency index, growth index and volatility index. EBIT increased 5.7% from -$3.96M to -$3.74M, net income increased 4.98% from -$4.22M to -$4.01M, and operating cash flow increased 3.16% from -$4.53M to -$4.39M.
E
Sell
8/10/2017Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 8/10/2017 due to a decline in the volatility index.
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 8/10/2017 due to a decline in the volatility index.
D
Sell
6/30/2017Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 6/30/2017 due to an increase in the volatility index and valuation index.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 6/30/2017 due to an increase in the volatility index and valuation index.
E
Sell
5/26/2017Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 5/26/2017 due to a decline in the volatility index and total return index.
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 5/26/2017 due to a decline in the volatility index and total return index.
D
Sell
5/11/2017Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 5/11/2017 due to a noticeable increase in the growth index and valuation index. Total revenue increased 88.52% from $540 to $1.02M, earnings per share increased from -$0.1284 to -$0.1, and EBIT increased 7.21% from -$4.27M to -$3.96M.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 5/11/2017 due to a noticeable increase in the growth index and valuation index. Total revenue increased 88.52% from $540 to $1.02M, earnings per share increased from -$0.1284 to -$0.1, and EBIT increased 7.21% from -$4.27M to -$3.96M.
E
Sell
3/9/2017Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 3/9/2017 due to a large decline in the growth index, efficiency index and total return index. Total revenue declined 49.77% from $1.08M to $540, EBIT declined 39.32% from -$3.93M to -$5.47M, and net income declined 36.72% from -$4.18M to -$5.71M.
Arcadia Biosciences, Inc. (RKDA) was downgraded to E+ from D- on 3/9/2017 due to a large decline in the growth index, efficiency index and total return index. Total revenue declined 49.77% from $1.08M to $540, EBIT declined 39.32% from -$3.93M to -$5.47M, and net income declined 36.72% from -$4.18M to -$5.71M.
D
Sell
9/30/2016Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to D- from D on 9/30/2016 due to a decline in the total return index and volatility index.
Arcadia Biosciences, Inc. (RKDA) was downgraded to D- from D on 9/30/2016 due to a decline in the total return index and volatility index.
D
Sell
9/15/2016Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D from D- on 09/15/2016.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D from D- on 09/15/2016.
D
Sell
2/1/2016Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 2/1/2016 due to a large increase in the efficiency index and growth index. Total revenue increased 27.48% from $1.43M to $1.82M, net income increased 25.62% from -$3.68M to -$4.62M, and EBIT increased 19.4% from -$3.55M to -$4.24M.
Arcadia Biosciences, Inc. (RKDA) was upgraded to D- from E+ on 2/1/2016 due to a large increase in the efficiency index and growth index. Total revenue increased 27.48% from $1.43M to $1.82M, net income increased 25.62% from -$3.68M to -$4.62M, and EBIT increased 19.4% from -$3.55M to -$4.24M.
E
Sell
11/2/2015Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to E+ from E on 11/2/2015 due to an increase in the valuation index.
Arcadia Biosciences, Inc. (RKDA) was upgraded to E+ from E on 11/2/2015 due to an increase in the valuation index.
E
Sell
9/28/2015Upgraded
Arcadia Biosciences, Inc. (RKDA) was upgraded to E from E- on 9/28/2015 due to an increase in the valuation index.
Arcadia Biosciences, Inc. (RKDA) was upgraded to E from E- on 9/28/2015 due to an increase in the valuation index.
E
Sell
8/25/2015Downgrade
Arcadia Biosciences, Inc. (RKDA) was downgraded to E- from E on 8/25/2015 due to a decline in the valuation index.
Arcadia Biosciences, Inc. (RKDA) was downgraded to E- from E on 8/25/2015 due to a decline in the valuation index.
E
Sell
8/10/2015None
Arcadia Biosciences, Inc. (RKDA) was downgraded to E from U on 08/10/2015.
Arcadia Biosciences, Inc. (RKDA) was downgraded to E from U on 08/10/2015.
NASDAQ
03/07/2025 1:11PM Eastern
Quotes delayed
